FDA Approves Celgene’s Otezla for PsA
The federal Food and Drug Administration has given its nod to Otezla (apremilast) for the treatment of adults with active psoriatic arthritis (PsA).
The federal Food and Drug Administration has given its nod to Otezla (apremilast) for the treatment of adults with active psoriatic arthritis (PsA).
Data presented at the Science of Skin Summit indicate topical regimens and treatments yield visible improvements in laxity, crepiness, and perceived age among individuals taking GLP-1 therapies.